Direct Copay Assistance Program News Today

The U.S. Supreme Court recently declined to review a Second Circuit decision that blocked Pfizer from implementing a cost sharing assistance program.

The U.S. Supreme Court recently declined to review a Second Circuit decision that blocked Pfizer from implementing a cost sharing assistance program. Pfizer had sought to cover...

This year, the Office of Inspector General ("OIG") and at least two federal courts have taken a clear stance against pharmaceutical manufacturers' attempts to offer cost-sharing subsidies...

The drugmaker may not pay Medicare beneficiaries' out-of-pocket costs for a heart medication priced at $225,000 a year, a federal appeals court decided.

By Jonathan Stempel NEW YORK (Reuters) - A federal appeals court on Monday rejected Pfizer Inc's challenge to a U.S. anti-kickback law that the drugma...

By Jonathan Stempel NEW YORK (Reuters) - A federal appeals court on Monday rejected Pfizer Inc's challenge to a U.S. anti-kickback law that the drugma...

By Jonathan Stempel NEW YORK (Reuters) - A federal appeals court on Monday rejected Pfizer Inc's challenge to a U.S. anti-kickback law that the drugma...

Key Points - Patient outcomes studies suggest a clinical benefit of co-pay programs, and a negative impact of co-pay accumulator programs. Co-pay programs...

Patient outcomes studies suggest a clinical benefit of co-pay programs, and a negative impact of co-pay accumulator programs.

Pfizer brought suit in direct challenge to application of health care fraud prohibitions enforced by Office of Inspector General for U.S. Department of Health and Human Services in S.D.N.Y, financial assistance to qualifying Medicare beneficiaries for tafamidis no AKS/BIS violation